What does this research mean for the field?

The combination of tyrosine kinase inhibitors and chemotherapy in children with Ph+ acute lymphoblastic leukemia maintains comparable outcomes while significantly reducing the need for hematopoietic stem cell transplantation. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

What question did this study set out to answer?

To evaluate the efficacy of combining tyrosine kinase inhibitors with chemotherapy in treating children with Ph+ acute lymphoblastic leukemia.

February 27, 20260 citations

View Full Paper

Combined Tyrosine Kinase Inhibitors and Chemotherapy Based on Minimal Residual Disease in Children With Ph+ Acute Lymphoblastic Leukemia: A Phase 2 Single-Arm Trial, JCCG ALL-Ph13.

ASAtsushi Sato YKYuichi Kodama HKHirohide Kawasaki

Key Points

To evaluate the efficacy of combining tyrosine kinase inhibitors with chemotherapy in treating children with Ph+ acute lymphoblastic leukemia.
Conducted a phase 2 single-arm trial
Focused on children with Ph+ ALL
Reduced intensity of hematopoietic stem cell transplantation (HSCT)
Evaluated outcomes based on minimal residual disease
Achieved comparable outcomes to previous studies
Significant reduction in HSCT
Indicated a need for optimizing TKI administration duration for better long-term event-free survival (EFS)

Abstract

Compared with Ph+ALL04, HSCT was substantially reduced in ALL-Ph13 while maintaining comparable outcomes. Further optimization of treatment, particularly the duration of TKI administration, is needed to maintain long-term EFS.

AI से पूछें

Bookmark

View Full Paper

AI से पूछें

Bookmark

View Full Paper

Combined Tyrosine Kinase Inhibitors and Chemotherapy Based on Minimal Residual Disease in Children With Ph+ Acute Lymphoblastic Leukemia: A Phase 2 Single-Arm Trial, JCCG ALL-Ph13.

Key Points

Abstract

Cite This Study

Also Consider

Also Consider